Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Go back to Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 35.67 +3.30 (10.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.37 | 52 Week High | $5.17 | |||
| Open | $31.76 | 52 Week Low | $0.94 | |||
| Day High | $35.88 | P/E | N/A | |||
| Day Low | $31.76 | EPS | $0.00 | |||
| Volume | 3,548,759 | |||||
